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Abstract 
Review on ADAMTS15, with data on DNA/RNA, 
on the protein encoded and where the gene is 
implicated. 
Identity 
HGNC (Hugo): ADAMTS15 
Location: 11q24.3 
DNA/RNA 
Description 
8 exons, spans approximately 27.66 Kb of genomic 
DNA in the centromere-to-telomere orientation. 
The translation initiation codon is located to exon 1, 
and the stop codon to exon 8. 
Protein 
Description 
The open reading fame encodes a 950 amino acid  
protein, with an estimated molecular weight of 
103,2 kDa. ADAMTS-15 shares a structural 
multidomain complex architecture with the rest of 
the members of the ADAMTS family.  
This organization includes a signal peptide, a 
prodomain involved in maintaining enzyme latency 
and a catalytic domain that contains the consensus 
sequence HEXXHGXXHD involved in the 
coordination of the zinc atom necessary for 
catalytic activiy of the enzyme.  
This sequence ends in an Asp residue which 
distinguishes ADAMTSs from other 
metalloproteases such as MMPs. Following this 
catalytic region there are several other domains 
characterized as disintegrin-like domain, a central 
thrombospondin-1 (TSP-1) motif, a cysteine-rich 
domain, a spacer region and two more TSP-1 
domains (Cal et al., 2002). 
Expression 
ADAMTS15 cDNA was originally cloned from 
both, a human liver and kidney fetal cDNA library 
(Cal et al., 2002). 
 
Domain organization of ADAMTS-15. Pro: prodomain; TSP: thrombospondin type-1 domains. 
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Later on, in the search for proteinases and 
proteinase inhibitors in articular cartilage from 
femoral heads of patients with end-stage 
osteoarthritis (OA) Kevorkian et al. found high 
levels of ADAMTS-15 expression in samples from 
both, OA patients as well as normal controls 
(Kevorkian et al., 2004). In relation with 
ADAMTS-15 participation in tumor progression its 
expression has been described in either normal cells 
or cells adjacent or marginal to cancer tissue in 
samples from colon adenocarcinoma as well as in 
samples from head and neck squamous cell 
carcinoma (Viloria et al., 2009; Stokes et al., 2010). 
Additionally ADAMTS-15 presence has also been 
detected in some breast and prostate cancer cell 
lines (Molokwu et al., 2010). 
Localisation 
Extracellular, mostly pericellular. 
Function 
Few studies describe ADAMTS-15 function 
beyond those describing its participation in cancer 
and osteoartritic processes. Regarding cancer, 
ADAMTS-15 has recently emerged as a putative 
tumor suppresor gene since it is downregulated in 
breast cancer, and functionally inactivated through 
specific mutations in colorectal cancer (Porter et al., 
2004; Porter et al., 2006; Viloria et al., 2009). In 
addition, aberrant expression of ADAMTS-15 is 
implicated in prostate cancer progression 
(Molokwu et al., 2010). The latest apparently 
results from the relationship between ADAMTS-15 
expression and versican degradation. Thus, 
ADAMTS-15 seems to be acting as a versican-
degrading enzyme whose accumulation potentially 
contributes to prostate cancer pathology (Cross et 
al., 2005). In this regard, versican seems to be one 
of the targets of ADAMTS-15 proteolityc activity 
which involves this protein in processes such as 
cancer or skeletal muscle fiber formation (Croos et 
al., 2005; Stupka et al., 2013; Dancevic et al., 
2013). 
Homology 
ADAMTS-15 belongs to the A Disintegrin And 
Metalloprotease Domains with ThromboSpondin 
motifs (ADAMTS) family, which consists of 19 
secreted zinc metalloproteinases (Porter et al., 
2005). All members of the family share the same 
structural domain design. ADAMTS-15 is, among 
all the members, closely related to ADAMTS-1 
which suggested its involvement in angiogenic 
processes (Cal et al., 2002). 
The ADAMTS15 gene is conserved in chimpanzee 
(Refseq: XM_522253), macaque (Refseq: 
XM_001113698), dog (Refseq: XM_005620295), 
cow (Refseq: NM_001192390), mouse (Refseq: 
NM_001024139), rat (Refseq: NM_001106810), 
chicken (Refseq: XM_417874), and zebrafish 
(Refseq: XM_001341842). 
Mutations 
Somatic 
ADAMTS15 was identified as one of the so-called 
CAN genes found to be mutated in a small set of 
colorectal cancers (Sjöblom et al., 2006). Two 
heterozigous somatic mutations were described out 
of eleven human cancer samples (cDNA: 
2309A>G, cDNA: 2632T>G). Functional relevance 
of mutations found in colorectal cancer were 
described for a deleterious single base mutation 
24544∆G affecting the two carboxy-terminal 
thrombospondin motifs of ADAMTS-15 (Viloria et 
al., 2009). The derived truncated form of 
ADAMTS-15 (ADAMTS15_G849fs) is barely 
found in the pericellular space of the cell being 
mostly liberated to the culture media. Functional 
studies revealed ADAMTS15_G849fs not showing 
the anti-tumoral properties of full length 
ADAMTS-15. In the same study, three other 
mutations where identified, a base pair mutation 
affecting the second TSP-1 domain (24616C>T), a 
silent base pair change (13777C>T) and another 
base deletion generating a completely truncated 
form of ADAMTS-15 (366∆) (Viloria et al., 2009). 
Implicated in 
Various cancers 
Note 
ADAMTS-15 has recently emerged as a putative 
tumor suppresor gene since it is downregulated in 
breast cancer, and functionally inactivated through 
specific mutations in colorectal cancer (Porter et al., 
2006; López-Otín et al., 2009; Viloria et al., 2009). 
In addition, aberrant expression of ADAMTS-15 is 
implicated in prostate cancer progression (Cross et 
al., 2005; Molokwu et al., 2010). The first 
indication regarding a potential protective role for 
ADAMTS15 derived from the observation that low 
ADAMTS15 expression levels coupled to high 
ADAMTS8 levels conferred poor prognosis to 
breast cancer patients (Porter et al., 2006). 
Moreover, ADAMTS15 was identified as one of the 
so-called CAN genes found to be mutated in a 
small set of colorectal cancers (Sjöblom et al., 
2006). Functional support to the putative relevance 
of ADAMTS-15 as a tumor suppresor protease was 
described after finding four additional mutations in 
ADAMTS-15 gene sequence in human colon 
carcinomas (Viloria et al., 2009). Two of the new 
mutations resulted in the generation of truncated 
forms of ADAMTS-15, one of them lacking the last 
two thrombospondin domains whereas the other 
originating a complete ADAMTS-15 knock-down. 
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Functional analysis revealed that the presence of the 
two last thrombospondin domains is important for 
the pericellular loacalization of ADAMTS-15 and 
affects the anti-tumoral function of full length 
ADAMTS-15 (Viloria et al., 2009; Dancevic et al., 
2013).  
More recently, ADAMTS-15 has been described as 
a head and neck squamous cell carcinoma 
(HNSCC)-associated proteinase since its expression 
is elevated (together with ADAMTS-1 and 
ADAMTS-8) in areas surrounding HNSCC tumor 
microenvironment (Demircan et al., 2009; Stokes et 
al., 2010).  
In addition, these three members of the ADAMTS 
family have elevated expression levels in HNSCC 
tumor versus normal tissue and in HNSCC derived 
cell lines vs normal keratinocytes (Stokes et al., 
2010).  
ADAMTS-15 has also been indirectly involved in 
androgen-mediated prostate cancer growth and 
proliferation, function that depends on ADAMTS-
15 versicanolytic activity (Cross et al., 2005; 
Molokwu et al., 2010).  
Molokwu et al identified one androgen-responsive 
element (ARE) in ADAMTS-15 promoter and 12 
more AREs in its gene sequence. In the same article 
the authors demonstrated ADAMTS-15 reduction 
both, at mRNA and protein levels, in the presence 
of dihidrotestorone (DHT).  
ADAMTS-15 down-regulation in prostate cancer 
resulted in high versican levels which is a poor 
prognosis indicator in these type of tumors 
(Ricciardelli et al., 1998; Luo et al., 2002; 
Molokwu et al., 2010). 
Colon cancer 
Note 
ADAMTS15 expression inversely correlates with 
histopathologic differentiation grade in human 
colorectal carcinomas when analyzing ADAMTS-
15 inmunostaining in normal colon epithelia, well-
differentiated tumors, moderately differentiated 
tumors, and poorly differentiated colorectal 
carcinomas (Viloria et al., 2009). 
Head and neck squamous carcinoma 
(HNSCC) 
Note 
ADAMTS15 mRNA levels, together with those of 
other ADAMTS members (ADAMTS1, 
ADAMTS4, ADAMTS5, ADAMTS8, 
ADAMTS9), were reduced in HNSCC primary 
tumors compared with paired non-cancerous tissues 
(Demircan et al., 2009). Regarding tumor 
microenvironment ADAMTS15 expression is 
elevated in adjacent and margin tissue when 
compared with tumor center tissue (Stokes et al., 
2010). 
Breast cancer 
Note 
ADAMTS15 elevated expression correlates with 
favorable outcome in patients with breast cancer 
(Porter et al., 2006). 
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